These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 18497054)

  • 1. Her-2/neu-induced "cytokine signature" in breast cancer.
    Vazquez-Martin A; Colomer R; Menendez JA
    Adv Exp Med Biol; 2008; 617():311-9. PubMed ID: 18497054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
    Vazquez-Martin A; Colomer R; Menendez JA
    Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer.
    Papadimitropoulou A; Vellon L; Atlas E; Steen TV; Cuyàs E; Verdura S; Espinoza I; Menendez JA; Lupu R
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase.
    Li J; Sidell N
    Int J Cancer; 2005 Oct; 117(1):14-20. PubMed ID: 15880583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling.
    Hamel KM; King CT; Cavalier MB; Liimatta KQ; Rozanski GL; King TA; Lam M; Bingham GC; Byrne CE; Xing D; Collins-Burow BM; Burow ME; Belgodere JA; Bratton MR; Bunnell BA; Martin EC
    Stem Cells Dev; 2022 Oct; 31(19-20):604-620. PubMed ID: 35579936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective dual role of mesenchymal stem cells in breast tumor microenvironment.
    Senst C; Nazari-Shafti T; Kruger S; Höner Zu Bentrup K; Dupin CL; Chaffin AE; Srivastav SK; Wörner PM; Abdel-Mageed AB; Alt EU; Izadpanah R
    Breast Cancer Res Treat; 2013 Jan; 137(1):69-79. PubMed ID: 23143214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines.
    Cristofanilli M; De Gasperis G; Zhang L; Hung MC; Gascoyne PR; Hortobagyi GN
    Clin Cancer Res; 2002 Feb; 8(2):615-9. PubMed ID: 11839684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues.
    Wilson KS; Roberts H; Leek R; Harris AL; Geradts J
    Am J Pathol; 2002 Oct; 161(4):1171-85. PubMed ID: 12368191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1.
    Lattrich C; Juhasz-Boess I; Ortmann O; Treeck O
    Oncol Rep; 2008 Mar; 19(3):811-7. PubMed ID: 18288420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of cytokines belonging to the interleukin-8 family by human gingival fibroblasts stimulated with interleukin-1 beta in culture.
    Odake H; Koizumi F; Hatakeyama S; Furuta I; Nakagawa H
    Exp Mol Pathol; 1993 Feb; 58(1):14-24. PubMed ID: 8454034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production.
    Shi Z; Yang WM; Chen LP; Yang DH; Zhou Q; Zhu J; Chen JJ; Huang RC; Chen ZS; Huang RP
    Breast Cancer Res Treat; 2012 Oct; 135(3):737-47. PubMed ID: 22923236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
    Bergenfelz C; Gaber A; Allaoui R; Mehmeti M; Jirström K; Leanderson T; Leandersson K
    Br J Cancer; 2015 Oct; 113(8):1234-43. PubMed ID: 26448179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
    Dragowska WH; Verreault M; Yapp DT; Warburton C; Edwards L; Ramsay EC; Huxham LA; Minchinton AI; Gelmon K; Bally MB
    Breast Cancer Res Treat; 2007 Dec; 106(3):319-31. PubMed ID: 17347776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL1 stimulates migration and invasion in ER‑negative breast cancer cells via activation of the ERK/MMP2/9 signaling axis.
    Yang C; Yu H; Chen R; Tao K; Jian L; Peng M; Li X; Liu M; Liu S
    Int J Oncol; 2019 Sep; 55(3):684-696. PubMed ID: 31322183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
    Simeone AM; Broemeling LD; Rosenblum J; Tari AM
    Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.